Ketamine Therapy and Spravato in Wilmington, NC

I’m preparing to offer IV ketamine infusions and Spravato (esketamine nasal spray) at my office in Wilmington, NC, with a planned opening in May 2027. I’m Dr. Shantanu Baghel, board-certified by the American Board of Psychiatry and Neurology (ABPN) in Psychiatry and Forensic Psychiatry. Both treatments may be options for adults whose depression hasn’t improved enough after 2 or more antidepressants.

Ketamine may work quickly. In a 2013 trial of 73 people with treatment-resistant depression, 64% responded 24 hours after a single IV dose of ketamine. In the comparison group, which got the sedative midazolam, 28% responded (PMID 23982301). Ketamine doesn’t help everyone, and your evaluation will help show whether it’s a good option for you.

Neither treatment is available yet. The waitlist is open now, and you can join it with a free 15-minute consultation by phone or video. When you book, mention ketamine or Spravato. I’ll contact you when I start scheduling, and I’ll update the planned date on this page if it changes.

  • I’ll do your evaluation and help you choose the treatment that fits you.
  • All treatment sessions will take place at my office in Wilmington, NC, in New Hanover County. Patients from nearby towns such as Leland, Hampstead, and Carolina Beach can join the waitlist. Your blood pressure and heart rate will be checked during and after each session.
  • Spravato is FDA-approved for treatment-resistant depression. The FDA approved ketamine (Ketalar) as an anesthetic, so using IV ketamine for depression is off-label.
  • IV ketamine will be self-pay. Many insurance plans cover Spravato.
  • You can keep your current psychiatrist, or I can manage all of your psychiatric care.

Book a free 15-minute consultation to join the waitlist.

How Treatment Will Work, Step by Step

You can book step 1 today. After your evaluation, I’ll help you choose between IV ketamine and Spravato.

Free 15-Minute Consultation I talk with you by phone or video, and I add you to the waitlist.
Psychiatric Evaluation I’ll review the medications you’ve tried and your medical history. You’ll also fill out the PHQ-9, a 9-question depression questionnaire. Then I’ll check whether ketamine or Spravato is safe for you.
Choose Your Treatment Together I’ll help you decide between IV ketamine and Spravato based on your history and what you prefer. I’ll also set your schedule.
Treatment Sessions in My Wilmington Office
IV Ketamine (Off-Label, Self-Pay) You’ll get a slow IV infusion over about 40 minutes. A typical series is 4 to 6 infusions over 2 to 4 weeks. Plan for about 2 hours in the office. Someone will need to drive you home. Don’t drive for 24 hours, and not before a restful night’s sleep.
Spravato (FDA-Approved) You’ll use the nasal spray yourself under observation in my office. Sessions will be twice a week for 4 weeks, then once a week for 4 weeks, then every 1 or 2 weeks. After each dose, you’ll stay in the office for at least 2 hours, until it’s safe for you to leave. Someone will need to drive you home. Don’t drive for 24 hours, and not before a restful night’s sleep.
Check Your Progress I’ll repeat the PHQ-9 during treatment. Then I’ll help you decide whether to continue, space out your sessions, or try a different treatment.
Psychiatric Care During and After Treatment
Join My Practice A flat $350 a month covers up to two visits with me. Ketamine and Spravato sessions will be paid for separately.
Keep Your Current Psychiatrist Your psychiatrist will keep managing your medications, and with your permission, I’ll send them updates on your treatment.

The IV schedule follows a 2026 consensus guideline from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners. It recommends about 4 to 6 infusions over 2 to 4 weeks (PMID 42144140).

The Spravato schedule and observation period come from the FDA prescribing information. It also says not to drive until the next day after a restful sleep, and I add a 24-hour minimum. The 24-hour driving rule for IV ketamine is in the FDA label for Ketalar, and I add a restful night’s sleep.

If treatment helps you, I’ll plan follow-up sessions with you to help keep the benefit.

My article on how many ketamine treatments people need for depression covers the trial evidence on series length and maintenance.


IV Ketamine Infusions and Spravato in Wilmington, NC: How They Compare

Both treatments use ketamine. IV ketamine contains both mirror-image forms of the molecule, and Spravato contains one of them, esketamine.

What to KnowIV KetamineSpravato
What it isKetamine given slowly through an IVEsketamine as a nasal spray
FDA statusFDA-approved as an anesthetic and used off-label for depressionFDA-approved for treatment-resistant depression, with an oral antidepressant or on its own
DoseBased on your weight, usually 0.5 mg/kg over about 40 minutes56 mg or 84 mg, using 2 or 3 nasal spray devices, 5 minutes apart
First monthUsually 4 to 6 infusions over 2 to 4 weeksTwice a week for 4 weeks
Time in the officeAbout 2 hoursAt least 2 hours after each dose
DrivingNo driving for 24 hours, and not before a restful night’s sleepNo driving for 24 hours, and not before a restful night’s sleep
PaymentSelf-payMany insurance plans cover it

With IV ketamine, I’ll set the dose to your weight and can adjust it from one infusion to the next. Spravato’s FDA prescribing information sets its dose and schedule.

A trial of about 400 adults is now enrolling to compare IV ketamine with Spravato directly (NCT06713616; PMID 41780747). Until it reports, I’ll help you choose between them at your evaluation.

My article on IV ketamine versus Spravato covers their side effects and the trial evidence in more detail.


What the Research Shows

In 2006, an early placebo-controlled trial of IV ketamine for treatment-resistant depression gave a single infusion to 17 people. The day after, 71% had responded (PMID 16894061).

A 2026 review pooled 26 randomized trials with 1,166 people. Ketamine infusions led to large drops in depressive symptoms within 24 hours. The benefit was still there at the end of a repeated series. The review had less data on how long the benefit lasted after the series ended (PMID 42090166).

In a 2023 trial of 676 people, 27.1% reached remission at 8 weeks with Spravato (PMID 37792613). People in the comparison group added extended-release quetiapine to their antidepressant. In that group, 17.6% reached remission. In January 2025, the FDA approved Spravato for use without an oral antidepressant (FDA approval letter), after a study of Spravato on its own (PMID 40601310).

Janssen, the company that makes Spravato, funded the 2019 and 2023 Spravato trials.


Who May Be a Good Fit

Ketamine and Spravato may be a good option if you’re an adult and 2 or more antidepressants haven’t fully relieved your depression.

At your evaluation, I’ll ask about each of the conditions below. Some make ketamine unsafe, and others call for extra care.

  • You’ve had psychosis, schizophrenia, or mania.
  • Your blood pressure is high and not under control.
  • You’ve had an aneurysm, an abnormal connection between blood vessels in the brain, or a bleed in the brain.
  • You’re pregnant or plan to become pregnant.
  • You’re using alcohol or drugs in a way that could interfere with treatment.

You’ll also need a ride home after every session. If that’s hard to arrange, tell me at your consultation, and I’ll help you plan around it.

Researchers are also studying IV ketamine for PTSD and OCD. In a small 2014 trial of 41 people with chronic PTSD, symptoms dropped more 24 hours after one ketamine infusion than after midazolam (PMID 24740528). In a larger 2022 trial of 158 veterans and service members, PTSD symptoms didn’t drop more with ketamine than with placebo (PMID 35046508).

In a small 2013 trial of 15 people with OCD, 4 of the 8 who got ketamine first responded 1 week later, compared with none of the 7 who got saline first (PMID 23783065). Both uses are off-label.


Safety and Monitoring in My Office

Both treatments will take place only in my office, under observation. Federal law lists ketamine as a controlled substance because it can be misused.

During a session, many people feel detached or dreamlike. Other common effects include dizziness and nausea. These effects usually start during the session and fade within a few hours (PMID 31109201).

Ketamine and Spravato also raise blood pressure for a short time. Spravato’s prescribing information says the rise peaks about 40 minutes after the dose and lasts about 4 hours.

Your blood pressure and heart rate will be checked before each session and again during and after it. If your blood pressure is too high that day, I’ll postpone the session (Spravato prescribing information).

ASKP3 2026 member logo

Cost and Insurance

IV ketamine will be self-pay. When you schedule your first infusion, you’ll get a written good faith estimate of your cost.

Many insurance plans cover Spravato. I’ll share how Spravato billing works before I start scheduling.

The consultation that puts you on the waitlist is free.


Your Psychiatric Care During and After Treatment

Ketamine or Spravato will be one part of your depression treatment. You’ll choose who manages the rest of your psychiatric care.

If you join my practice, I’ll manage your medications and track your progress with the PHQ-9.

If you keep your current psychiatrist, they’ll keep managing your medications. With your permission, I’ll send them updates after your evaluation and during treatment.

If ketamine or Spravato isn’t the right fit, I’ll talk with you about other options. My post on what to do when an antidepressant isn’t working covers dose changes, switches, and add-on medications. My page on depression treatment in North Carolina describes the rest of my approach.

I see patients by video anywhere in North Carolina, and in person at my Wilmington office by request.

Book a free 15-minute consultation to join the waitlist.


Frequently Asked Questions

When will ketamine and Spravato be available?

The planned opening is May 2027. I’ll contact everyone on the waitlist as soon as I start scheduling, and I’ll update this page if the date changes. To join the waitlist, book a free consultation.

Where will ketamine therapy take place?

Ketamine therapy will take place at my office in Wilmington, NC, in New Hanover County. Patients from Wilmington and across southeastern North Carolina can join the waitlist.

Is IV ketamine FDA-approved for depression?

The FDA approved ketamine as an anesthetic, so using IV ketamine for depression is off-label. Spravato is FDA-approved for treatment-resistant depression.

Can I get Spravato online or at home?

Your free consultation can be by phone or video. Each Spravato dose will be in my office. Spravato’s FDA prescribing information requires a certified healthcare setting and at least 2 hours of observation after each dose. I’ll give IV ketamine only in my office too.

Does insurance cover ketamine?

IV ketamine will be self-pay. Many insurance plans cover Spravato.

What does ketamine feel like?

Many people feel detached or dreamlike during a session, and sights and sounds can seem different. These effects usually fade within a few hours.

How quickly does ketamine work?

Ketamine may work within a day for some people. In one trial, 64% responded 24 hours after a single IV dose (PMID 23982301). With Spravato, I’ll review your progress at the end of the first 4 weeks.

Do I need to stop my antidepressant?

You can usually keep taking it. Spravato is approved with an oral antidepressant or on its own. I’ll review every medication you take at your evaluation.

Is ketamine addictive?

Ketamine can be misused, and the Spravato label carries a boxed warning about abuse and misuse. The warning also covers sedation, dissociation (feeling detached), slowed breathing, and suicidal thoughts and behaviors in younger patients. That’s why both treatments will be given only in my office, under observation. I’ll also ask about alcohol and drug use at your evaluation.

Do I need a referral?

You can book a free consultation yourself. Your insurance plan may need a prior authorization for Spravato.

Can I keep my current psychiatrist?

Your psychiatrist can keep managing your medications while I give you ketamine or Spravato. With your permission, I’ll keep them updated.


IV ketamine and Spravato aren’t available yet at Baghel Psychiatry. Using IV ketamine for depression is off-label. This page is for educational purposes only and isn’t medical advice. Don’t start, stop, or change any medication without talking to your prescribing clinician. The waitlist isn’t for urgent care. If you’re in danger now, call 911. If you’re thinking about suicide, call or text 988.

References (15)
  1. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. PMID: 16894061.
  2. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. PMID: 23982301.
  3. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2026;83(7):714-731. PMID: 42090166.
  4. Mathai DS, Cluck M, Aslam AM, et al. Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). J Affect Disord. 2026;411:121970. PMID: 42144140.
  5. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428-438. PMID: 31109201.
  6. Reif A, Bitter I, Buyze J, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389(14):1298-1309. PMID: 37792613.
  7. Janik A, Qiu X, Lane R, et al. Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2025;82(9):877-887. PMID: 40601310.
  8. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688. PMID: 24740528.
  9. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475-2483. PMID: 23783065.
  10. Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. PMID: 35046508.
  11. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemp Clin Trials. 2026;164:108273. PMID: 41780747.
  12. Janssen Pharmaceuticals, Inc. SPRAVATO (esketamine) nasal spray: prescribing information. Revised March 2026. DailyMed.
  13. Par Health USA. KETALAR (ketamine hydrochloride) injection: prescribing information. Revised March 2026. FDA label.
  14. U.S. Food and Drug Administration. Supplement approval letter, NDA 211243/S-016 (SPRAVATO monotherapy for treatment-resistant depression). January 17, 2025. FDA letter.
  15. ClinicalTrials.gov. NCT06713616. Comparing the effectiveness of racemic ketamine versus esketamine for depression (PCORI-funded; Yale University). Study record.